These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 15306092)

  • 1. New approaches to anticoagulation in atrial fibrillation.
    Petersen P
    Curr Cardiol Rep; 2004 Sep; 6(5):354-64. PubMed ID: 15306092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ximelagatran: oral direct thrombin inhibition as anticoagulant therapy in atrial fibrillation.
    Halperin JL
    J Am Coll Cardiol; 2005 Jan; 45(1):1-9. PubMed ID: 15629364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of stroke in patients with atrial fibrillation.
    Olsson SB; Halperin JL
    Semin Vasc Med; 2005 Aug; 5(3):285-92. PubMed ID: 16123916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
    Diener HC;
    Cerebrovasc Dis; 2006; 21(4):279-93. PubMed ID: 16449807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial.
    Albers GW; Diener HC; Frison L; Grind M; Nevinson M; Partridge S; Halperin JL; Horrow J; Olsson SB; Petersen P; Vahanian A;
    JAMA; 2005 Feb; 293(6):690-8. PubMed ID: 15701910
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct thrombin inhibition and stroke prevention in elderly patients with atrial fibrillation: experience from the SPORTIF III and V Trials.
    Ford GA; Choy AM; Deedwania P; Karalis DG; Lindholm CJ; Pluta W; Frison L; Olsson SB;
    Stroke; 2007 Nov; 38(11):2965-71. PubMed ID: 17885258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preventing stroke in atrial fibrillation: the SPORTIF programme.
    Lip GY
    Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():25-30. PubMed ID: 15812201
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study.
    Petersen P; Grind M; Adler J;
    J Am Coll Cardiol; 2003 May; 41(9):1445-51. PubMed ID: 12742279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, in atrial fibrillation patients receiving long-term anticoagulation therapy.
    Bååthe S; Hamrén B; Karlsson MO; Wollbratt M; Grind M; Eriksson UG
    Clin Pharmacokinet; 2006; 45(8):803-19. PubMed ID: 16884319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation?
    Reiffel JA
    Curr Opin Cardiol; 2004 Jan; 19(1):58-63. PubMed ID: 14688636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.
    Olsson SB;
    Lancet; 2003 Nov; 362(9397):1691-8. PubMed ID: 14643116
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor.
    Halperin JL
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):163-74. PubMed ID: 15151465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral direct thrombin inhibitors in clinical development.
    Gustafsson D
    J Intern Med; 2003 Oct; 254(4):322-34. PubMed ID: 12974871
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ximelagatran for stroke prevention in atrial fibrillation.
    Boos CJ; Lip GY
    Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):551-63. PubMed ID: 16076267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stroke prevention in atrial fibrillation: pooled analysis of SPORTIF III and V trials.
    Albers GW;
    Am J Manag Care; 2004 Dec; 10(14 Suppl):S462-9; discussion S469-73. PubMed ID: 15696910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ximelagatran: an orally active direct thrombin inhibitor.
    Gulseth MP
    Am J Health Syst Pharm; 2005 Jul; 62(14):1451-67. PubMed ID: 15998925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
    Selçuk H; Selçuk MT; Maden O
    Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
    Flaker GC; Gruber M; Connolly SJ; Goldman S; Chaparro S; Vahanian A; Halinen MO; Horrow J; Halperin JL;
    Am Heart J; 2006 Nov; 152(5):967-73. PubMed ID: 17070169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Ximelagatran: a promising new drug for oral anticoagulation].
    Scardi S; Giansante C
    Monaldi Arch Chest Dis; 2004 Mar; 62(1):34-9. PubMed ID: 15211735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ximelagatran.
    Choudhury A; Goyal D; Lip GY
    Drugs Today (Barc); 2006 Jan; 42(1):3-19. PubMed ID: 16511607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.